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Abstract
This study sought to define the role of memory lymphocytes in the protection from homologous influenza A virus re-
challenge in rhesus macaques. Depleting monoclonal antibodies (mAb) were administered to the animals prior to their
second experimental inoculation with a human seasonal influenza A virus strain. Treatment with either anti-CD8a or anti-
CD20 mAbs prior to re-challenge had minimal effect on influenza A virus replication. Thus, in non-human primates with pre-
existing anti-influenza A antibodies, memory B cells and CD8a
+ T cells do not contribute to the control of virus replication
after re-challenge with a homologous strain of influenza A virus.
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Introduction
Seasonal influenza A virus infection is a highly contagious, acute
respiratory tract disease of humans that causes substantial
morbidity and mortality, particularly among the young, old, and
immunocompromised [1]. After infection of people with an
antigenically novel influenza A virus strain there is a 2–3 day
period of virus replication and the full range of adaptive immune
responses develops in response to the antigen produced [2,3].
Influenza-specific antibodies are detected within 7 to 12 days of
infection and gradually decline over the first 6 months post
infection. Neutralizing antibodies specific for influenza hemagglu-
tinin (HA) and neuraminidase (NA) correlate with protection from
disease after exposure to a homologous influenza A virus [2].
Although most humans mount T cell responses to the immuno-
dominant Matrix 1 protein after natural infection [4]; the human
T cell response seldom extends to the other influenza A virus
proteins [4]. Further, the role of antiviral T cell responses in
controlling influenza A virus replication in people is undefined.
Humans previously infected with one strain of influenza A virus
are solidly protected from disease upon subsequent exposure to the
homologous influenza A virus and this protection is associated
with the presence of high titer antiviral antibodies [5]. Upon re-
exposure to a homologous virus, virus replication is either
completely blocked or severely blunted with no virus detectable
after 48 hours. The nature of the immunity that provides this
protection is not fully understood although there is little time for
the expansion of memory T cells or the elaboration of humoral
and cellular effector molecules by antigen-specific lymphocytes.
Immunity to human influenza viruses is often studied in mice
and ferrets. Human influenza viruses normally replicate efficiently
in mice only after adaptation [6] but ferrets are highly susceptible
to infection with human influenza viruses and appear to better
recapitulate human innate immunity, disease severity and
transmissibility than mice [7,8,9]. Guinea pigs are also susceptible
to human influenza infection and they have been used to study
human influenza A virus transmission [10]. Nonhuman primate
models are less often used in influenza research but they are
commonly employed in AIDS research and are excellent models
of the human immune and respiratory systems due to their
relatively close phylogenetic relationship with people. Macaques
are naturally and experimentally infected with human influenza A
viruses with varying degrees of morbidity [11,12,13]. The kinetics
of viral replication and the nature of the antiviral immune
response in experimentally infected humans [3] and macaques
[12] are similar, as strain-specific CD4
+ and CD8
+ T cell and
antibody responses arise within 14 days of infection. Human
seasonal influenza A viruses infect and replicate in the respiratory
tract of macaques causing either asymptomatic or mild clinical
infections [11,12,14]. The pandemic avian H5N1 [15] and 1918
H1N1 viruses [16] cause acute respiratory distress syndrome in
macaques that is very similar to humans.
It has been shown that rhesus macaques previously infected with
H3N2 Aichi influenza A virus are protected from homologous re-
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21756challenge 90 days later to the point that no infectious virus can be
isolated. [11]. Thus influenza A virus infection of rhesus macaques
induces potent antiviral immune effector mechanisms that can
effectively block virus replication upon re-exposure. While it is
generally accepted that influenza A virus hemagglutinin (HA)
specific antibodies protect against rechallenge with antigenically
matched viruses, the relative contribution of antibodies and other
immune effector mechanisms to control of influenza virus
replication in the respiratory tract is unknown. In the current
study we administered either an anti-CD20 B cell depleting mAb
or an anti-CD8a T cell and NK cell depleting mAb to rhesus
macaques prior to their second experimental inoculation with a
human seasonal influenza A virus strain. Despite the near
complete depletion of peripheral CD20+ B cells or CD8+ T cells
and the lack of an anamnestic antibody response in the B cell
depleted animals, the level of viral replication in the intact and
lymphocyte depleted animals were similar.
Methods
Ethics Statement/Animals
All animals used in this study were adult rhesus macaques
(Macaca mulatta) housed at the California National Primate
Research Center in accordance with the recommendations of the
Association for Assessment and Accreditation of Laboratory
Animal Care International Standards and with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The Institutional Animal Use
and Care Committee of the University of California, Davis,
approved these experiments (Protocol #11479). For blood
collection, animals were anesthetized with 10 mg/kg ketamine
hydrochloride (Park-Davis) injected i.m. For virus inoculation and
respiratory secretion sample collection, animals were additionally
anesthetized with 15–30 mg/kg Domitor (Orion Pharma) injected
i.m., and anesthesia was reversed with 0.07–0.15 mg/kg Anti-
sedan (Pfizer Animal Health) injected i.m. All efforts were made to
minimize suffering. Details of animal welfare and steps taken to
ameliorate suffering were in accordance with the recommenda-
tions of the Weatherall report, ‘‘The use of non-human primates in
research’’. Animals were housed in an air-conditioned facility with
an ambient temperature of 21–25uC, a relative humidity of 40%–
60% and a 12 h light/dark cycle. Animals were individually
housed in suspended stainless steel wire-bottomed cages and
provided with a commercial primate diet. Fresh fruit was provided
once daily and water was freely available at all times.
Monkey lymphocyte depletion, inoculation, sample
processing and analysis of lymphocyte populations in
blood
Nine animals assigned to 3 experimental groups were
challenged with a previously described human influenza A virus
isolate, A/Memphis/7/2001 (H1N1) [12], and re-challenged 4–8
months later using the same virus stock (Tables 1 and 2). Using
methods previously described [17,18], group A macaques (n=3)
were treated with a CD8a
+ lymphocyte (CD8
+ T cells and NK
cells) depleting mAb (cM-T807, Centocor, Malvern, Pa.; 50 mg/
kg; IV infusion) 3 days prior to re-challenge. Group B macaques
(n=5) were treated with a CD20
+ B cell depleting mAb
(rituximab, Genentech, Inc., South San Francisco, CA; 50 mg/
kg; IV infusion) 28, 14, and 3 days prior to day of re-challenge.
The human influenza A virus isolate used in this study, A/
Memphis/7/2001 (H1N1), was generously provide by Richard
Webby at the St. Jude’s Children Hospital, Memphis, TN. This
isolate was isolated on MDCK and was not passaged further prior
to expansion in MDCK cells (American Type Culture Collection,
Manassas, VA) to produce the virus stock used for animal
inoculations. The virus stock had a titer of 10
6.5 TCID50/ml on
MDCK cells using the method of Reed and Muench [19]. The
intranasal/intratracheal/conjunctival influenza A virus inocula-
tion procedure and the respiratory secretion sample collection
procedure have been previously described [12]. For both the initial
and re-challenge inoculations, animals were inoculated with 6 ml
of the virus stock instilled into the trachea, 1 ml of virus stock
dripped intranasally, and a drop of virus stock in each conjunctiva.
Blood samples were collected on days 228, 221, 214, 0, 7, 14
and 28 relative to the day of influenza A virus re-challenge. The
percentage of CD3
+ CD8
+ T cells, CD3
2 CD16
+ NK cells and
CD20
+ B cells in peripheral blood was determined by flow
cytometric analysis as previously described [17,18].
Titration of infectious influenza virus and viral RNA in
respiratory secretions
The 50% tissue culture infectious dose (TCID50) of infectious
virus in respiratory secretions was determined by end-point culture
on MDCK cells as previously described [12]. Further, the amount
of virion-associated RNA (vRNA) in respiratory secretions was
determined by RT-PCR as previously described [12].
Influenza Antibody ELISA and HI assays
Titers of anti-influenza antibodies were determined by a
modification of a method previously described [12,20].
Tracheal Sample Cytokine mRNA Expression Levels
The method for assessment of host gene expression in tracheal
secretions has been published [12]. Briefly, total RNA was isolated
from the cellular pellets with TRIzolH (Invitrogen) according to
manufacturer’s instructions. RNA samples were DNase-treated
and cDNA was prepared using random hexamer primers
(Amersham-Pharmcia Biotech Inc.) and SuperScript III reverse
transcriptase (Invitrogen). Cytokine mRNA levels were determined
by RT-PCR as described previously [21,22]. The GAPDH
housekeeping gene and the target gene from each sample were
run in parallel in the same plate. The reaction was carried out in a
96-well optical plate (Applied Biosystems) in a 25 ml reaction
volume containing 5 ml cDNA plus 20 ml Mastermix (Applied
Biosystems). All sequences were amplified using the 7900 default
amplification program. The results were analyzed with the SDS
7900 system software, version 2.1 (Applied Biosystems). Cytokine
mRNA expression levels were calculated from normalized DCT
values. CT values correspond to the cycle number at which the
fluorescence due to enrichment of the PCR product reaches
significant levels above the background fluorescence (threshold). In
this analysis, the CT value for the housekeeping gene (GAPDH) is
subtracted from the CT value of the target (cytokine) gene (DCT).
In general, the DCT value for the influenza A-infected sample is
then subtracted from the pre-infection DCT value (DDCT).
Assuming that the target gene (cytokine) and the reference gene
(GAPDH) are amplified with the same efficiency (data not shown),
the increase in cytokine mRNA levels in test samples is then
calculated as follows: increase=2
2DDC
T (user bulletin no. 2, ABI
Prism 7700 Sequence Detection System: Applied Biosystems).
Cytokine mRNA levels are expressed as the increase or decrease
relative to the level for that cytokine in the individual monkey’s
pretreatment secretion sample. Because the mRNA expression
level of housekeeping genes such as GAPDH can change under
activating conditions, we were careful to use the same input
amount of RNA for experimental samples in the PCR reactions.
Control of Influenza A Virus after Re-Challenge
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RNA consistently resulted in similar PCR amplification (CT)
values for GAPDH. Therefore, GAPDH expression in trachea was
not differentially regulated among the animals in this study.
Statistical Analysis
Statistics are reported as the mean and the standard error of
the mean for each group using Prism 5.0a software (GraphPad)
and data are presented as the probability and test used for
analysis. Mean levels of lymphocyte subsets, vRNA and TCID50
in the treated groups were independently compared to the
untreated control animal group with a one-tailed unpaired T test.
Linear regression analysis and Pearson’s Correlation analysis
were used to define the relationship between serum antibody
titers and virus replication and the results of both analyses are
reported.
Table 1. IgG titers in plasma after the first and second inoculations withA/Memphis/7/01.
Weeks after Influenza A virus inoculation
1st inoculation 2nd inoculation
Animal
Number
Months between
inoculations Treatment 0 2 0
a 124
30924 4 None 800
b 80,000 160,000 640,000 640,000 640,000
30933 7 None 800 32,000 20,000 640,000 160,000 160,000
33470 8 None 800 64,000 40,000 320,000 320,000 160,000
MEAN 800 58,667 73,333 533,333
c 373,333
c 320,000
30811 7 a-CD8 800 64,000 40,000 320,000 640,000 640,000
30831 7 a-CD8 800 64,000 80,000 320,000 640,000 640,000
30851 7 a-CD8 800 160,000 80,000 320,000 640,000 640,000
MEAN 800 96,000 66,667 320,000
c 640,000
c 640,000
30616 7 a-CD20 800 64,000 160,000 160,000 160,000 160,000
30921 7 a-CD20 800 80,000 80,000 80,000 160,000 160,000
35125 4 a-CD20 800 32,000 40,000 40,000 80,000 160,000
MEAN 800 58,667 93,333 93,333
c 133,333
c 160,000
a=day of re-inoculation with A/Memphis/7/01.
b=endpoint dilution titers to whole disrupted A/Memphis/7/01. A titer of 1:800 indicates the sample was below the cutoff established by screening plasma from A/
Memphis/7/01 naı ¨ve animals.
c=day 7 PC titers of the groups are significantly different (p=0.033, Kruskal-Wallis test) and the difference between the untreated and B cell depleted animal groups
is also significant (p,0.05, Dunn’s multiple comparison test.).
doi:10.1371/journal.pone.0021756.t001
Table 2. HI titers in plasma after the first and second inoculations with A/Memphis/7/01.
Weeks after Influenza A virus inoculation
1st inoculation 2nd inoculation
Animal Number Months between inoculations Treatment 0 2 0
a 12 4
30924 4 None 8
b 128 320 1280 1280 1280
30933 7 None 8 32 64 1024 1024 2048
33470 8 None 8 64 256 512 1024 1024
MEAN 8 75 213 939 1109 1451
30811 7 a-CD8 8 128 80 640 2560 2560
30831 7 a-CD8 8 128 320 640 2560 2560
30851 7 a-CD8 8 1024 1280 1280 1280 2560
MEAN 8 427 560 853 2133 2560
30616 7 a-CD20 16 128 512 512 512 1024
30921 7 a-CD20 4 128 512 512 1024 2048
35125 4 a-CD20 4 16 128 128 512 512
MEAN 8 91 384 384 683 1195
a=day of re-inoculation with A/Memphis/7/01.
b=HA Inhibition titer to A/Memphis/7/01.
doi:10.1371/journal.pone.0021756.t002
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Antibody responses and Influenza A virus replication
after the initial inoculation
Prior to inoculation, 8 of 9 animals had plasma IgG antibody
titers to A/Memphis/7/01 that were below the cutoff (1:800) for
the assay (Table 1) and HI titers ranged from 1:4 to 1:16 (Table 2).
In contrast to the other 8 monkeys, both pre-inoculation plasma
samples from monkey 35125 had O.D. values at 1:800 that were
just at the cut-off, consistent with the presence of low-titer A/
Memphis/7/01-specific binding antibodies on the day of chal-
lenge (Table 1), however A/Memphis/7/01-specific HI antibodies
of this animal were undetectable at the lowest dilution (1:4) tested
(Table 2). By 2 weeks after inoculation, all 9 animals had made
strong anti-influenza antibody responses, binding IgG antibody
titers ranged from 1:32,000–1:160,000 (Table 1) and HI titers
ranged from 1:16–1:1024 (Table 2). After the first experimental
inoculation with A/Memphis/7/01, infectious virus was isolated
from the tracheal secretions of all 9 animals in this study. As we
have previously described, virus replication peaked 24–48 hours
after inoculation (mean peak titer of 10
4.1 TCID50/ml; Fig. 1),
steadily declined but was detectable in all 9 animals at day 3 PI,
until day 7 when infectious virus could not be isolated from any of
the animals (Fig. 1). Assays to quantify influenza virus RNA in the
secretions of these 9 animals were not performed after the initial
infection, however we previously reported [12] that after an initial
challenge with A/Memphis/7/01, the peak vRNA levels in
tracheal secretions of 3 animals ranged from 5.4–6.4 log10 vRNA
copies/ml secretions (Table 3).
Anti-CD8a and anti-CD20 mAbs effectively deplete
targeted lymphocyte populations in the blood of treated
animals
Adult rhesus macaques previously infected with A/Memphis/
7/01 were infused with either anti-CD8a (n=3), anti-CD20 mAbs
(n=3) or left untreated (n=3) prior to re-challenge with A/
Memphis/7/01 (Tables 1 and 2, Fig. 2). On the day of influenza A
virus re-challenge, 28 days after the first anti-CD20 infusion
(Fig. 2), the mean number of circulating CD20
+ B cells in the 3
treated animals (0.0460.2 B cells/ml blood) was 1000 fold lower
compared to untreated animals (393670 B cells/ml blood) and this
difference was highly significant (p,0.0001, unpaired one tail T
test). Three days after anti-CD8 infusion (Fig. 2), on the day of re-
challenge, the mean numbers of CD8
+ T cells and CD8
+ NK cells
in the blood of the 3 treated animals (0.860.4 CD8
+ T cells/ml
blood, 0.260.5 NK cells/ml blood) were also reduced approxi-
mately 1000 fold compared to the 3 untreated animals (2686131
CD8
+ T cells/ml blood, 111623 CD8
+ NK cells/ml blood) and
these differences were significant (p,0.0001 for CD8+ T cells and
p,0.0001 for NK cells, unpaired one tail T tests). The CD20+ B
cell and CD8a+ lymphocyte populations remained depleted from
the day of influenza re-challenge to 7 days PC (Fig. 2), completely
blocking anamnestic responses by these lymphocyte subsets for the
first week after re-challenge (see below). Further we, and others,
have shown that if the anti-CD20 and anti-CD8 Mabs effectively
deplete peripheral lymphocyte subsets then more than 90% of
their target cells are also depleted from the tissues of rhesus
macaques [18,23,24,25,26,27,28]. Thus, although the level of
lymphocyte depletion in the respiratory tract was not examined in
the above studies, it is reasonable to assume that the Mabs
depleted most of the target lymphocytes from tissues of the animals
in the present study.
Influenza A virus replication is well-controlled upon
homologous re-challenge of untreated animals
On the day of re-challenge with A/Memphis/7/01, the 3
untreated animals had a mean A/Memphis/7/01 HI titer of 1:213
(range 1:64–1:320) (Table 2). After homologous re-challenge, low
levels of virus could be isolated from the tracheal secretions of only
2 of the 3 animals (Fig. 3a) compared to the mean peak titer of
10
4.1 TCID50/ml (Fig. 1) in the naı ¨ve animals after the first A/
Memphis/7/01 inoculation. On days 1 and 2 after homologous
re-challenge, vRNA was detected in tracheal secretions of all 3
untreated animals at very low levels (mean peak titer of 10
4.1
vRNA copies/ml). Based on our previously published [12] and
shown in Table 3, we expect influenza RNA levels of 10
5–10
6
copies/ml of tracheal secretions 24–48 hours after A/Memphis/
7/01 inoculation of naı ¨ve animals. We have also shown that
24 hours after inoculation of 4 naı ¨ve animals with heat-killed A/
Memphis/7/01, vRNA levels ranged from 10
2.4–10
3.5 vRNA
copies/ml secretions [12] (Table 3). Because influenza A virus
vRNA levels in the secretions after homologous re-challenge are
higher (0.6–1.7 log10) than after inoculation with heat-killed virus,
some low level replication is occurring after re-challenge. Thus,
based on both infectious virus levels and vRNA levels in tracheal
secretions it is clear that influenza A virus replication was very
well-controlled in rhesus macaques that were re-challenged 4
months after being infected with the same virus.
Limited role of memory CD8
+ or CD20
+ lymphocytes in
control of viral replication after homologous influenza A
virus re-challenge
On the day of re-challenge, the 3 anti-CD20 mAb-treated
animals had a mean A/Memphis/7/01 HI titer of 1:384 (range
1:280–1:512); and the 3 anti-CD8a mAb -treated animals had a
mean A/Memphis/7/01 HI titer of 1:560 (range 1:80–1:1280)
(Table 2). After A/Memphis/7/2001 re-challenge, the mean peak
virus titer (TCID50/ml) and the mean area under the curve (AUC;
virus titer from day 0 to day 7 after re-challenge) in the tracheal
secretions of the anti-CD8a and anti-CD20 mAb treated animals
were separately compared to the untreated animals.
Similar to the control group, animals treated with either anti-
CD8a or anti-CD20 mAbs prior to re-challenge had very little
detectable influenza A virus replication (Fig. 3). In fact, infectious
virus was isolated from only 1 CD8a-depleted animal; and both
Figure 1. Influenza virus replication in the lower respiratory
tract after A/Memphis/7/01 inoculation. Mean infectious virus titer
in tracheal secretions (TCID50/ml) of nine inoculated rhesus macaques.
doi:10.1371/journal.pone.0021756.g001
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animal were very low (Fig. 3a). Further on days 1 and 2 after re-
challenge, similar levels of vRNA (log10 copies/ml) were detected
in tracheal secretions of the anti-CD8a-, anti-CD20 mAb-treated
and untreated animals (Fig. 3b).
To gauge the ability of the different animal groups to control
virus replication after homologous re-challenge relative to the first
A/Memphis/7/01 inoculation, peak infectious titers and AUC of
the infectious virus titer from day 0 to 7 were compared (Fig. 4). As
the levels of virus replication were similar in the treated and
untreated animals after rechallenge, all animals were grouped for
this comparison. Both the peak TCID50 and the TCID50 AUC
were significantly lower after re-challenge than after the initial
infection, clearly illustrating the effectiveness of anti-influenza
immunity against matched virus strains.
Limited role of local innate immune responses in control
of viral replication after homologous influenza A virus re-
challenge
The mRNA levels of IFN-a, MxA, OAS and IL-6 in tracheal
secretions of an animal at 24 hours after re-challenge were
compared to levels in the same animal 72 hours prior to re-
challenge (Table 3). For comparison, the previously published data
[12] for a similar experiment performed on 3 animals after their
initial infection with A/Memphis/7/01 and on 4 animals after
they were inoculated with heat inactivated A/Memphis/7/01 are
shown in Table 3. In contrast to the high mRNA levels of all 4
genes in tracheal secretions of 3 animals after an initial H1N1
infection, target gene mRNA levels among the 9 study animals
remained uniformly low (Table 3). In fact, after H1N1 re-
challenge, host gene expression levels in the tracheal secretions of
the all animals were similar, regardless of intervention (Table 3).
These results indicate that local innate immune responses did not
contribute to control of viral replication after homologous
influenza A virus re-challenge even in the lymphocyte depleted
animals.
Pre-existing strain-specific anti-influenza antibody titers
are unaffected by treatment with anti-CD8a or anti-CD20
mAbs
Prior to the initial challenge with A/Memphis/7/01 IgG
antibodies were undetectable above the 1:800 plasma dilution cut-
Table 3. Influenza virus RNA and host gene mRNA levels in tracheal secretions 24 hours after initial A/Memphis/7/2001 (H1N1)
challenge; H1N1 re-challenge; or challenge with heat-inactivated H1N1.
mRNA expression fold change relative to pre exposure
Animal Number Peak log10 vRNA copies/ml IFN-a OAS MxA IL-6
No Treatment prior to H1N1 re-challenge
30924 3.7 25.1 4.3 3.2 10.9
30933 3.9 NA
a 27.6 11.0 3.4
33470 4.6 162.3 32.3 15.5 13.6
Mean 4.1 78.6 21.4 9.9 9.3
Anti-CD8 Treatment prior to H1N1 re-challenge
30811 4.8 NA NA NA 86.9
30831 3.1 3.4 5.1 3.5 22.7
30851 2.2 2.5 3.9 5.0 12.6
Mean 3.4 2.9 4.5 4.3 40.7
Anti-CD20 treatment prior to H1N1 re-challenge
30616 2.5 22.7 2.5 1.5 22.1
30921 4.2 NA NA NA NA
35125 4.3 234.6 5.7 16.4 6.0
Mean 3.7 218.6 4.1 8.9 14.0
Initial H1N1 challenge
b
33073 5.8 3910.6 53.7 29.4 287.8
33178 5.4 11340.0 101.8 15.3 72.5
34421 6.4 1606.1 65.4 19.2 5786.6
Mean 5.9 5618.9 73.6 21.3 2048.9
Initial challenge with Heat-inactivated H1N1
b
31392 2.9 211.3 1.7 5.3 22.8
31625 3.5 40.6 2.0 5.5 NA
31705 2.4 1.1 1.8 2.6 24.3
31864 3.1 214.0 21.9 10.8 22.5
Mean 3.0 4.1 0.9 6.0 23.2
a=target gene mRNA levels could not be determined due to poor amplification of GAPDH mRNA.
b=data adapted from Carroll et al, J. Immunol. 2008 [12].
doi:10.1371/journal.pone.0021756.t003
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animals had plasma HI titers to A/Memphis/7/01 greater than
1:16 before initial infection (Table 2). By day 14 after the first
infection, anti-influenza IgG and HI antibody titers among the 9
study animals had increased dramatically. On the day of
rechallenge, the anti-influenza antibody responses remained strong
in all animals (Tables 1 and 2), despite the fact that the 3 anti-
CD20 mAb treated animals were completely depleted of
circulating CD20+ B cells prior to re-challenge. Thus, on the
day of homologous influenza virus A re-challenge, the animals
treated with anti-CD20, anti-CD8a, and the untreated animals
had similarly high IgG and HI responses (Tables 1 and 2). The
persistent strong antibody responses despite anti-CD20 treatment
presumably reflect the 21-day half-life of plasma IgG and the fact
that plasma cells were unaffected by the treatment due to the lack
of CD20 expression [29,30].
To understand the effect of the anti-CD20 mAb treatment on
the anamnestic anti-influenza antibody responses after re-chal-
lenge IgG and HI antibodies were assessed. From the day of re-
challenge to 7 days after re-challenge, there was no change in anti-
influenza IgG and HI titers of the anti-CD20-mAb treated
animals. In contrast anti-CD8a-mAb treated animals had a 4.8
Figure 2. The effect of anti-CD20 and anti-CD8a infusion on
CD20
+ B cells, CD3
+ CD8a
+ T cells and CD3
2 CD8a
+ NK cells in
blood of animals at the time of influenza virus re-challenge. a)
CD20
+ B cells in blood, b) CD3+ CD8a
+ T cells and, c) CD3
2 CD8a
+ NK
cells. Green symbols and lines denote the anti-CD20 monkeys (n=3),
blue symbols and lines denote the anti-CD8a-treated monkeys (n=3)
and red symbols and lines denote un-treated monkeys (n=3). Day 0
indicates the day of influenza re-challenge. Anti-CD20 was infused 28,
14, and 3 days prior to the day of influenza re-challenge, anti-CD8 was
infused 3 days prior to virus inoculation. Arrows indicate the timing of
the antibody infusions; blue arrow indicates anti-CD8a infusion and
green arrows indicate anti-CD20 infusions.
doi:10.1371/journal.pone.0021756.g002
Figure 3. Influenza virus replication in the lower respiratory
tract after A/Memphis/7/01 inoculation. A) Mean infectious virus
titer in tracheal secretions (TCID50/ml). Inset; mean tracheal secretion
peak TCID50 (B) Mean vRNA copy number in tracheal secretions (Log10
copies/ml). Inset; mean tracheal secretion peak vRNA.N No lymphocyte
depletion before re-challenge (n=3) & CD8a
+ T cell and NK cell
depletion before re-challenge (n=3) m CD20
+ B cell depletion before
re-challenge (n=3).
doi:10.1371/journal.pone.0021756.g003
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antibody titers, while the untreated animals had 4.4 fold increase
in HI antibody titers and 7.3 fold increase in IgG antibody titers
(Tables 1 and 2). Thus the CD20 lymphocyte depletion completely
blocked the normal anamnestic antibody responses to homologous
influenza A virus re-challenge.
Relationship between HI titers on the day of homologous
influenza A virus re-challenge and control of virus
replication
To better understand the relationship between HI titers on the
day of A/Memphis/7/01 re-challenge and viral replication, linear
regression and Pearson’s correlation analyses were undertaken
(Fig. 5a). Although infectious virus was undetectable in 6 of the 9
animals after homologous re-challenge, the 2 animals with the
highest peak TCID50 had the lowest HI titers on the day of re-
challenge. Thus, the linear regression analysis suggested there was
significant negative correlation (p=0.032 and r
2=0.5) between the
HI titer on the day of re-challenge and the level of viral replication
after the re-challenge; however, Pearson’s correlation analysis did
not demonstrate a significant relationship. In addition, among the 6
animals with an intact B cell population on the day of challenge,
there was significant positive correlation between the change in HI
titer between the day of re-challenge and day 14 after re-challenge
(p=0.002 and r
2=0.76, Pearson Correlation coefficient p,0.05)
and peak TCID50 after re-challenge. Thus in the 2 animals with the
highest detectable peak TCID50 there was a 32-fold change in HI
titer between the day of re-challenge and day 14 after re-challenge.
While inthe 4 animalswith undetectableinfectiousvirus or very low
peak TCID50 there was a #8-fold change in HI titer between the
day of re-challenge and day 14 after re-challenge. Thus large
increasesinHI titeronlyoccurred inanimalsthat had demonstrable
productive infection after re-challenge.
Discussion
The results presented here demonstrate that, as in humans,
rhesus monkeys control seasonal influenza A virus replication after
secondary exposure to homologous virus. Further, IFN-a induced
antiviral mediators, effector CD8
+ T cells and anamnestic B cell
responses do not seem to contribute to control of virus replication
after homologous influenza A virus re-challenge of rhesus
macaques (Fig. 3, Table 3). However, the level of strain-specific
HI antibodies and anti-influenza IgG in plasma on the day of
homologous influenza A virus re-challenge inversely correlated
with the level of virus replication in the rhesus macaques (Fig. 5A).
As the level of virus replication in lymphocyte-depleted animals
was similar to intact animals regardless of which effector
lymphocyte arm was depleted, it seems unlikely that the intact
subset contributed to control of virus replication upon re-exposure.
However, to confirm this conclusion an experiment that depletes
both B cells and CD8a+ lymphocytes prior to infection could be
conducted. These results strongly imply that anti-influenza
antibodies in plasma at the time of homologous influenza A virus
re-challenge are an immune correlate for the control of virus
replication in these previously infected animals.
Epidemiologic studies inhumanshavecorrelated the incidence of
influenza A virus infection with the level of pre-existing HI serum
antibodies [31,32,33,34] or binding anti-influenza antibodies [5]
making it possible to estimate the titer of HI antibodies that is
necessary to prevent virus replication and limit disease. In three
successive epidemics of antigenically-drifted H3N2 influenza A
viruses, the 50% protective HI titer (PT50) was estimated to be
between 1:12–1:24, and no infections were recorded in persons with
HI titers $1:48 [33]. In addition, during an outbreak of infection
withwild-type influenza A/Victoria/3/75virus, 0 of 19 people with
pre-epidemic HI titers .1:40 became infected [35]. Perhaps most
convincingly, a similar correlation was found in challenge
experiments of immunized humans using a variety of influenza A
virus strains, including the A/Hong Kong/68, with a calculated
PT50 from 1:18 to 1:36 based on virus isolation or a 4-fold rise in
plasma HI titer to the challenge virus as measures of infection [36].
In the rhesus macaques studied here, all animals had HI titers
.1:64 on the day of homologous influenza A virus re-challenge and
they all controlled viral replication relative to their initial infection
withA/Memphis/7/01.Ofnote,althoughtheHItiter didcorrelate
with the extent of viral replication and shedding, a serum HI titer of
1:64 wasnotcompletelyprotectiveas3animalswithHItiters.1:64
had evidence of low level viral shedding (Fig. 3). As serum HI titer is
themajorimmunecorrelateforcontrolofinfluenzavirusreplication
upona second experimentalexposureto homologous virus inrhesus
Figure 4. Comparison of influenza virus replication in the lower
respiratory tract after the first and second A/Memphis/7/01
inoculations. (A) Mean peak infectious virus titer in tracheal secretions
(TCID50/ml). (B) Mean AUC of the infectious virus titer in tracheal
secretions from day 0 to day 7 after re-challenge.
doi:10.1371/journal.pone.0021756.g004
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responsible for protection from uncontrolled virus replication and
disease may be similar in humans and macaques. It is important to
recognize that the correlation between serum HI levels and
protection does not imply causality, and neutralizing antibody must
be present within the respiratory tract to prevent virus replication in
therespiratoryepithelium.Infact,werecentlyshowedthatinrhesus
macaques immunized with an inactivated influenza vaccine
(Fluzone) IgG anti-influenza antibody titers in the tracheal
secretions and plasma of the animals 3 days prior to H1N1
challenge inversely correlated with virus replication after challenge
[37]. Understanding the relative importance of local and systemic
B-cell responses in maintaining a persistent level of protective HI
antibody within the respiratory tract would facilitate the develop-
ment of more effective influenza vaccines.
The 4–7 month interval between the first H1N1 influenza A virus
infection and the homologous re-challenge of the rhesus monkeys in
this study approximates the length of an influenza season, and thus
the results reported here provide a ready explanation for resistance to
a second infection with a homologous influenza A virus in a single
season. However, this study did not attempt to identify the immune
mechanisms responsible for long-term protection from homologous
influenza A virus re-challenge. Some studies in humans suggest that
HI titers remain above a PT50 of 1:16–32 for at least 25–30 years. In
fact people infected with the H1N1 subtype before 1950 were
subsequently protected when this subtype reappeared in 1977, and
similarly, people born before 1892 and infected with the H3N2
subtype were protected from disease when this subtype reappeared in
1968 [38,39]. Persistent HI titers to H3 found in the serum of the
individuals born before 1892 and persistent HI titers to H1 in persons
born before 1950 are thought to account for this extraordinarily long-
lived protection [38]. The mechanism behind this long-lived plasma
antibody response is unknown but it is thought to be dependent on
memory CD4+ T cells and memory B cells (reviewed in [40]). The
persistence of these long-lived memory lymphocytes may be aided by
repeated exposure to, and infections with, unrelated influenza A
viruses; a hypothesis that could be directly tested in rhesus macaques
that live for 20–30 years in captivity.
This study clearly shows that in primates, memory B cells and
CD8a
+ T cells do not contribute to the control of virus replication
after re-challenge with a homologous H1N1 strain of influenza A.
In future studies, administration of anti-CD8a, anti-CD4 or anti-
CD20 depleting antibodies in rhesus macaques challenged with
antigenically-drifted and heterosubtypic influenza A viruses could
be used to define the nature of protective, vaccine-induced, and
infection-induced immune responses to progressively divergent
viruses. This information could then be used to rationally guide
the development of universal influenza vaccines.
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